0001192482-21-000212.txt : 20210303 0001192482-21-000212.hdr.sgml : 20210303 20210303200239 ACCESSION NUMBER: 0001192482-21-000212 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210301 FILED AS OF DATE: 20210303 DATE AS OF CHANGE: 20210303 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ciaffoni Joseph CENTRAL INDEX KEY: 0001443841 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37372 FILM NUMBER: 21711852 MAIL ADDRESS: STREET 1: 100 TECHNOLOGY CENTER DRIVE CITY: STOUGHTON STATE: MA ZIP: 02072 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: COLLEGIUM PHARMACEUTICAL, INC CENTRAL INDEX KEY: 0001267565 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: VA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 TECHNOLOGY CENTER DRIVE CITY: STOUGHTON STATE: MA ZIP: 02072 BUSINESS PHONE: 781-713-3699 MAIL ADDRESS: STREET 1: 100 TECHNOLOGY CENTER DRIVE CITY: STOUGHTON STATE: MA ZIP: 02072 FORMER COMPANY: FORMER CONFORMED NAME: COLLEGIUM PHARMACEUTICAL INC DATE OF NAME CHANGE: 20031020 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2021-03-01 0001267565 COLLEGIUM PHARMACEUTICAL, INC COLL 0001443841 Ciaffoni Joseph C/O COLLEGIUM PHARMACEUTICAL, INC. 100 TECHNOLOGY CENTER DRIVE STOUGHTON MA 02072 1 1 0 0 President and CEO Common Stock 2021-03-01 4 M 0 48616 8.22 A 343075 D Common Stock 2021-03-01 4 S 0 54959 22.56 D 288116 D Common Stock 2021-03-01 4 S 0 9809 23.3 D 278307 D Stock Option (Right to Purchase) 8.22 2021-03-01 4 M 0 48616 0 D 2027-05-31 Common Stock 48616 16205 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2020. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.01 to $22.98, inclusive. The reporting person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2) and (3). The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.00 to $23.54, inclusive. 48,616 shares under the option are exercisable. The option, initially representing a right to purchase a total of 259,283 shares, vests and becomes exercisable over a four-year period commencing on May 31, 2017. Twenty-five percent (25%) of the option vested and became exercisable on May 31, 2018 and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) at the end of each quarterly period over the remaining three years of the four-year period, subject to the reporting person's continued service with the Issuer. /s/ Paul Brannelly as Attorney-In-Fact For Joseph Ciaffoni 2021-03-03